Cost-effectiveness of new WHO recommendations for prevention of mother-to-child transmission of HIV in a resource-limited setting

AIDS

Volumn 25, Issue 8, 2011, Pages 1093-1102

  Shah, Maunank ^a,d   Johns, Benjamin ^b   Abimiku, Alash'Le ^c   Walker, Damian G ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d CRB2 Building   (United States)

Author keywords

Africa; AIDS; antiretroviral therapy; cost effectiveness; HIV; prevention of mother to child transmission vertical transmission

Indexed keywords

EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE;

ARTICLE; BREAST FEEDING; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; DELIVERY; FEMALE; GESTATIONAL AGE; HEALTH CARE; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LABOR; NIGERIA; OUTCOME ASSESSMENT; PREGNANCY RATE; PREGNANT WOMAN; PRENATAL PERIOD; PRIORITY JOURNAL; PUERPERIUM; QUALITY ADJUSTED LIFE YEAR; SHORT COURSE THERAPY; SINGLE DRUG DOSE; VERTICAL TRANSMISSION; WORLD HEALTH ORGANIZATION;

EID: 85027924145     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834670b9     Document Type: Article

References (39)

1. WHO. PMTCT Strategic vision 2010-2015: preventing motherto -child transmission of HIV. Geneva: World Health Organization; .2010. http://www.who.int/hiv/pub/mtct/strategic-vision/ en/index.html [Accessed February 2010].
2. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic. Geneva: UNAIDS; 2010. http://www.unaids.org/en/ media/unaids/contentassets/documents/ unaidspublication/ 2010/20101123-globalreport-en.pdf [Accessed February 2011].
3. Adeyi O, Kanki P, Odutolu O, Idoko J. AIDS in Nigeria: a nation on the threshold. Harvard University Press; 2005.
4. Chama CM, Audu BM, Kyari O. Prevention of mother-to-child transmission of HIV at Maiduguri, Nigeria. J Obstet Gynaecol 2004; 24:266-269. (Pubitemid 38491195)
5. WHO. Epidemiology Fact Sheet on HIV/AIDS - Nigeria 2008. Geneva: World Health Organization; 2008. http://apps.who.int/ globalatlas/predefinedReports/ EFS2008/full/EFS2008-NG.pdf [Accessed December 2010].
6. Audu RA, Salu OB, Musa AZ, Onyewuche J, Funso-Adebayo EO, Iroha EO, et al. Estimation of the rate of mother to child transmission of HIV in Nigeria. Afr J Med Med Sci 2006; 35:121-124.
7. Federal Ministry of Health - Nigeria. National PMTCT and HIV & infant feeding guidelines Nigeria; 2009.
8. Office of Inspector General. Audit of USAID/Nigeria's PEPFARFunded Activities and Commodities for the Prevention of Mother-to-Child Transmission of HIV. Report No. 7-620-10- 002-P: USAID; 2010.
9. Chanda J. ICAP-Nigeria PMTCT: expanding from sd-NVP to HAART. Intl Center for AIDS Care and Tx Programs (ICAP) Collaborative Pediatric Strategic Planning Workshop; 2007.
10. Becquet R, Ekouevi DK, Arrive E, Stringer JS, Meda N, Chaix ML, et al. Universal antiretroviral therapy for pregnant and breastfeeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis 2009; 49:1936-1945.
11. WHO. Rapid advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infections in infants. Geneva: World Health Organization; 2009. http://www.who. int/hiv/pub/mtct/advice/en/index.html [Accessed February 2010].
12. Chama CM, Bello M, Ajayi BA, Zarma S, Gashau W. The use of highly active antiretroviral therapy for the prevention of mother-to-child transmission of the human immunodeficiency virus in Nigeria. J Obstet Gynaecol 2010; 30:362-366.
13. National Population Commission (NPC) Nigeria and ICF Macro. Nigeria Demographic and Health Survey 2008. Abuja, Nigeria: National Population Commission and ICF Macro; 2009.
14. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge: Harvard University Press; 1996.
15. WHO. Life Tables forWHOMember States - 2008. http://www. who.int/healthinfo/statistics/mortality-life-tables/en/ [Accessed June 2010].
16. Walker N, Schwartlander B, Bryce J. Meeting international goals in child survival and HIV/AIDS. Lancet 2002; 360: 284-289. (Pubitemid 34874720)
17. Spira R, Lepage P, Msellati P, Van De Perre P, Leroy V, Simonon A, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. Pediatrics 1999; 104:e56.
18. Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner WM, Van Dyke RB. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr 2010; 53:86-94.
19. PEPFAR-Nigeria. Drug and Laboratory Costs Report. Personal Communication with Institute for Human Virology - Nigeria; May 2010.
20. WHO. World Health Organization Statistical Information System. http://apps.who.int/whosis/data/Search.jsp [Accessed June 2010].
21. Kilewo C, Karlsson K, Ngarina M, Massawe A, Lyamuya E, Swai A, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dares Salaam, Tanzania: the Mitra Plus study. J Acquir Immune Defic Syndr 2009; 52:406-416.
22. International Drug Price Indicator Guide. http://erc.msh.org/ dmpguide/index.cfm?language=english&action=newyear&dis play=yes&module=dmp&year=2009 [Accessed August 2010].
23. WHO. Choosing Interventions that Are Cost-Effective (WHOCHOICE) - unit costs for patient services in Nigeria. http:// www.who.int/choice/country/nga/ cost/en/index.html [Accessed June 2010].
24. Kombe GC, Nwagbara C, Galaty D. How much does it cost to provide comprehensive antiretroviral treatment (ART) in the public sector in Nigeria and who pays for it. [Accessed November 2010].
25. Onwujekwe O, Dike N, Chukwuka C, Uzochukwu B, Onyedum C, Onoka C, Ichoku H. Examining catastrophic costs and benefit incidence of subsidized antiretroviral treatment (ART) programme in south-east Nigeria. Health Policy 2009; 90:223-229.
26. Sweat MD, O'Reilly KR, Schmid GP, Denison J, de Zoysa I. Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries. AIDS (London, England) 2004; 18:1661-1671. (Pubitemid 39095783)
27. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIVinfected infants. N Engl J Med 2008; 359:2233-2244.
28. Becquet R, Mofenson LM. Early antiretroviral therapy of HIV-infected infants in resource-limited countries: possible, feasible, effective and challenging. AIDS 2008; 22:1365-1368.
29. Murray CJ, Acharya AK. Understanding DALYs (disabilityadjusted life years). J Health Econ 1997; 16:703-730.
30. Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 2001; 16:326-331. (Pubitemid 32911160)
31. Abimiku AG. Building laboratory infrastructure to support scale-up of HIV/AIDS treatment, care, and prevention: in-country experience. Am J Clin Pathol 2009; 131:875-886.
32. Meyer-Rath G, Violari A, Cotton M, Ndibongo B, Brennan A, Long L, et al. The cost of early vs. deferred paediatric antiretroviral treatment in South Africa: a comparative economic analysis of the first year of the CHER trial. International AIDS Conference. Vienna, Austria; 2010.
33. IMF. World Economic and Financial Surveys-International Monetary Fund. http://imf.org/external/pubs/ft/weo/2009/02/ weodata/index.aspx [Accessed June 2010].
34. WHO. Macroeconomics and health: investing in health for economic development. Report on the Commission on Macroeconomics and Health. WHO; Geneva, Switzerland; 2001. http://whqlibdoc.who.int/publications/2001/924154550x.pdf [Accessed January 2011].
35. Shillcutt SD, Walker DG, Goodman CA, Mills AJ. Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 2009; 27:903-917.
36. WHO. Investing in Health Research and Development Report of the Ad Hoc committee on Health Research Relating to Future Intervention Options. Geneva; 1996. http://whqlibdoc.who.int/ hq/1996/TDR-GEN-96.2.pdf [Accessed February 2011].
37. WHO. Summary Country Profile for HIV/AIDS Treatment Scale- UP - Nigeria. Geneva: WHO; 2005. http://www.who.int/hiv/ HIVCP-NGA.pdf [Accessed February 2011].
38. WHO. African Regional National Health Accounts Data 2001- .2005. http://www.afro.who.int/en/clusters-a-programmes/hss/ health-financing-a-social- protection/hfs-publications.html [Accessed March 2010].
39. Ekanem EE, Gbadegesin A. Voluntary counselling and testing (VCT) for human immunodeficiency virus: a study on acceptability by Nigerian women attending antenatal clinics. Afr J Reprod Health 2004; 8:91-100.